AOD-9604 vs Tesamorelin: Which Burns Body Fat Faster?

Q: What is the difference between AOD-9604 and Tesamorelin?

AOD-9604 is a fragment of human growth hormone (amino acids 176 to 191) that targets fat breakdown directly without raising IGF-1 or other GH-related hormones. Tesamorelin is a GHRH analog that stimulates the pituitary to release full growth hormone, which then reduces visceral fat. They work through completely different mechanisms despite sharing a fat-loss outcome.

Q: Does AOD-9604 raise IGF-1 or growth hormone?

No. AOD-9604 is a fragment of GH that retains the fat-breakdown signal but does not activate the full GH pathway. It does not raise IGF-1 levels, which is a key reason some people prefer it to full GH or GHRH-based compounds.

Q: Is Tesamorelin FDA-approved?

Yes. Tesamorelin is FDA-approved under the brand name Egrifta for reducing excess visceral fat in adults with HIV-associated lipodystrophy. Outside that indication, it is used as a research compound.

Q: Which is better for general fat loss, AOD-9604 or Tesamorelin?

Tesamorelin has stronger human clinical trial evidence, specifically for visceral (deep belly) fat reduction. AOD-9604 has less human trial data and its fat-loss effects in people have not been consistently demonstrated in controlled trials. Both are research-use compounds outside their specific approved indications.

Built by medical professionals, gym rats, and experienced biohackers

Quick Answer

Tesamorelin has stronger human evidence; AOD-9604 has a cleaner mechanism but weaker proof in people. Tesamorelin is for people targeting visceral fat with clinical trial data behind the choice. AOD-9604 is for people who want fat-targeted effects without raising IGF-1, and accept limited human trial evidence.

AOD-9604 vs Tesamorelin is a genuinely unique comparison because these two compounds look like they belong in the same category (both involve GH and fat loss) but they work in completely opposite directions.

What Is AOD-9604?

AOD-9604 is a synthetic peptide made from amino acids 176 to 191 of the human growth hormone (HGH) molecule. Researchers isolated this portion of HGH because it appeared to contain the fat-breakdown signal while leaving out the growth-promoting and IGF-1-raising signals .

The idea is simple: get the fat-loss part of HGH without the risks or complexity of full GH therapy.

AOD-9604 is thought to work by stimulating fat breakdown (a process called lipolysis) and slowing the conversion of food into fat . Notably, it does not appear to raise IGF-1 or blood glucose levels, which are two concerns associated with full GH use .

Research doses typically range from 250 to 500mcg per day, injected under the skin (source). AOD-9604 has no FDA approval for any use. Early human trials for obesity were conducted but did not result in approval .

What Is Tesamorelin?

Tesamorelin is a synthetic copy of GHRH (growth hormone releasing hormone), which is the signal your brain sends to the pituitary gland to trigger GH secretion.

When you inject tesamorelin, the pituitary gland responds by releasing GH. That GH then circulates through the body and, among other effects, reduces visceral fat (the deep fat that accumulates around organs in the belly) .

Unlike AOD-9604, tesamorelin does raise GH and IGF-1 levels. This is how it works, but it is also why some people prefer AOD-9604's more targeted approach.

Tesamorelin is FDA-approved under the brand name Egrifta for HIV-associated lipodystrophy (a condition where antiretroviral therapy causes excess visceral fat buildup) . In human trials, it reduced visceral fat by 15 to 18% over 26 weeks (source). The standard dose is 2mg per day, injected under the skin .

How Do AOD-9604 and Tesamorelin Differ?

Feature	AOD-9604	Tesamorelin
What it is	Fragment of HGH (aa 176 to 191)	GHRH analog
Mechanism	Direct fat breakdown signal	Triggers pituitary to release full GH
Raises IGF-1?	No	Yes
Raises blood GH?	No (not a GH stimulator)	Yes (via pituitary)
Target	Fat cells directly	Visceral fat via GH cascade
Typical research dose	250 to 500mcg/day	2mg/day
FDA approval	No	Yes (HIV lipodystrophy only)
Human clinical evidence	Limited; trials did not reach approval	Moderate; two Phase 3 trials
Common side effects	Injection site reactions; generally well-tolerated	Fluid retention, joint pain, injection site reactions

Mechanism

AOD-9604 works like a partial key. It fits into the fat cell's receptor just enough to turn on the fat-burning signal, but it does not activate the broader GH pathway that drives muscle growth, IGF-1 elevation, or blood sugar changes.

Tesamorelin works by knocking on the pituitary's door and saying "release GH now." The pituitary responds, GH enters the bloodstream, and the body's full GH response follows. Visceral fat reduction is one result of that full response.

Evidence Level

Tesamorelin has a clear human evidence base: it completed Phase 3 trials and earned FDA approval for a specific population (source). The visceral fat reduction was statistically significant and reproducible .

AOD-9604 ran human trials for obesity but did not demonstrate sufficient effectiveness to achieve approval . Its mechanism is elegant in theory, but the human trial results were disappointing. That does not mean it has no effect, but be clear that the clinical evidence for fat loss in people is weak.

Can You Stack AOD-9604 and Tesamorelin?

This would be an unusual combination. They work through very different mechanisms, and in theory they could be used together, but there is no meaningful human research on this combination (source).

Most practitioners who use tesamorelin do not add AOD-9604 because tesamorelin already addresses visceral fat through a well-studied pathway. Using both would add cost and injection burden without clear additional benefit.

If you are managing a complex protocol with multiple compounds, DoseVault helps you log what you take, when you take it, and how your body measurements change, so you can actually see what is working.

Which Do People Pick, and When?

This is general guidance, not personalized medical advice.

People tend to choose Tesamorelin when:
- Their main goal is reducing visceral (deep belly) fat
- They want a compound with an actual FDA approval and human trial data
- They are working with a physician who can prescribe it
- They are comfortable with GH and IGF-1 levels rising as part of the mechanism

People tend to choose AOD-9604 when:
- They want fat-targeted effects without raising IGF-1
- They are concerned about the broader hormonal effects of stimulating full GH release
- They prefer a simpler, more localized mechanism despite weaker clinical evidence

The choice often comes down to how important the IGF-1 question is to the individual and what level of evidence they require before using a compound.

Frequently Asked Questions

What is the difference between AOD-9604 and Tesamorelin?
AOD-9604 is a GH fragment that targets fat breakdown directly without raising IGF-1. Tesamorelin stimulates the pituitary to release full GH, which then reduces visceral fat. Completely different mechanisms, similar fat-loss goals.

Does AOD-9604 raise IGF-1 or growth hormone?
No. AOD-9604 retains the fat-breakdown signal from HGH but does not activate the full GH pathway. It does not raise IGF-1, blood GH, or blood glucose.

Is Tesamorelin FDA-approved?
Yes. Tesamorelin (Egrifta) is FDA-approved for reducing excess visceral fat in adults with HIV-associated lipodystrophy. Outside that use, it is a research compound.

Which is better for general fat loss, AOD-9604 or Tesamorelin?
Tesamorelin has stronger human clinical evidence. AOD-9604 failed to achieve approval in its human obesity trials. For a general audience using these as research compounds, tesamorelin has the more reliable track record.

Disclaimer

This page is for educational purposes only and is not medical advice. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. AOD-9604 has no FDA approval for any use. Do not start any peptide protocol without guidance from a licensed healthcare provider. Consult a qualified clinician before using either compound.

Ready to track your protocol? DoseVault is built to help you log injections, track body composition goals, and monitor how your body responds over time.

Built by medical professionals, gym rats, and experienced biohackers